Advanced Medical Solutions Dividends - AMS

Advanced Medical Solutions Dividends - AMS

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Advanced Medical Solutions Group Plc AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change Price Change % Stock Price Last Trade
-3.00 -1.05% 283.00 10:09:51
Open Price Low Price High Price Close Price Previous Close
285.00 281.50 285.00 286.00
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Advanced Medical Solutions AMS Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
16/09/2020InterimGBX0.531/12/201931/12/202024/09/202025/09/202023/10/20200
11/03/2020FinalGBX1.0531/12/201831/12/201928/05/202029/05/202019/06/20201.55
11/09/2019InterimGBX0.531/12/201831/12/201926/09/201927/09/201925/10/20190
13/03/2019FinalGBX0.931/12/201731/12/201823/05/201924/05/201914/06/20191.32
12/09/2018InterimGBX0.4231/12/201731/12/201828/09/201829/09/201826/10/20180
14/03/2018FinalGBX0.7531/12/201631/12/201724/05/201825/05/201815/06/20181.1
13/09/2017InterimGBX0.3531/12/201631/12/201728/09/201729/09/201727/10/20170
14/03/2017FinalGBX0.6231/12/201531/12/201625/05/201726/05/201716/06/20170.92
14/09/2016InterimGBX0.331/12/201531/12/201629/09/201630/09/201628/10/20160
16/03/2016FinalGBX0.5531/12/201431/12/201519/05/201620/05/201610/06/20160.8
09/09/2015InterimGBX0.2531/12/201431/12/201501/10/201502/10/201530/10/20150
04/03/2015FinalGBX0.4831/12/201331/12/201407/05/201508/05/201529/05/20150.7
10/09/2014InterimGBX0.2231/12/201331/12/201401/10/201403/10/201431/10/20140
06/03/2014FinalGBX0.4131/12/201231/12/201330/04/201402/05/201428/05/20140.6
11/09/2013InterimGBX0.1931/12/201231/12/201302/10/201304/10/201301/11/20130
06/03/2013FinalGBX0.3531/12/201131/12/201201/05/201303/05/201328/05/20130.52
05/09/2012InterimGBX0.1731/12/201131/12/201203/10/201205/10/201202/11/20120
07/03/2012FinalGBX0.3131/12/201031/12/201116/05/201218/05/201215/06/20120.45
07/09/2011InterimGBX0.14531/12/201031/12/201105/10/201107/10/201104/11/20110
08/03/2011FinalGBX0.3831/12/200931/12/201011/05/201113/05/201110/06/20110.38

Top Dividend Posts

DateSubject
08/4/2021
17:59
dozey3: Aiui Rapid Liquiband was expected to get FDA approval in Q1 this year, and that should help, plus of course the very successful vaccination programme in the US which should soon increase elective surgery to normal levels. AMS could prove a tasty morsel for one of the many giant US medical companies.
07/4/2021
14:18
dealit: AMS are a rock solid Company with a good management team. They are waiting approval from FDA on some next generation products which IMHO will take the share price to a higher level.
21/2/2021
22:47
thetwentiestrader: Hi All, an article on the investment case for AMS post half year 2020 results. Available here: hxxps://www.thetwentiestrader.com/post/advanced-medical-solutions-licking-its-wounds
21/2/2021
16:43
cynic1: AMS were first tipped in the MoS in 2002. Just wish I'd bought more at 10p. Solid company with good forward thinking management.
21/2/2021
13:40
cynic1: AMS one of the top 10 biggest bargain tips in the MOS
09/12/2020
21:53
wetdream: dealit, I have a love/hate relationship with AMS... I’ve always thought of them as a well-run, if undynamic, company with a solid product range and in a pretty ‘fireproofR17; business sector. A bit too dependent on acquisitions (that I struggle to appreciate) but hey-ho, ‘steady as she goes’. But then along came Trump with his ‘America First’ campaign in the middle of the pandemic and AMS just got left behind. Not entirely their fault, but irritating that it’ s set them back as you point out at least 12 months. They’ve done well to hold on to some quality funds as supporters, so I guess extra patience is required.
09/12/2020
15:42
dealit: wetdream-I have posted part of an announcement from earlier in the year and feel that AMS S/P should head north on FDI approval IMHO.---- The LiquiBand® XL critical pilot study has been completed with three different formulations successfully meeting our objective of 14-day wear time. However, some of the variants demonstrated extended set time. The lead formulation, which we believe maximises our potential for long term commercial success on all product features, is an accelerated formulation of LiquiBand® that will require additional stability and biocompatibility data along with a repeat of the clinical study as part of the FDA filing. The additional work required on this lead formulation means that we now expect to file for 510K approval in the first quarter of 2021. We expect the financial impact of this delayed approval to be offset by the stronger than anticipated LiquiBand® market share improvement and short term commercial agreements with US hospitals to encourage additional LiquiBand® adoption in the run up to the LiquiBand® XL approval. Once approved, LiquiBand® XL will allow entry into the market for care of larger wounds and unlock further growth potential in the LiquiBand® business with all partners.
23/11/2020
16:31
energeticbacker: Advanced Medical Solutions acquires Raleigh Adhesive Coatings, reports Investor's Champion. For the 6 months ending 31 October Raleigh generated revenue of £3.9m and operating profit of £0.8m, compared to the prior year’s loss of £0.3m. The £22m acquisition cost therefore represents quite a multiple, suggesting AMS thinks highly of this business.
20/11/2020
16:49
energeticbacker: AMS received CE mark approval for its Silicone PHMB Foam Dressing, which sits alongside the previously US approval for this product. AMS has had a tough time over the pandemic which has led to the deferral of elective surgeries and woundcare clinics, however, according to Investor's Champion this innovative business remains in good shape and should continue to thrive when markets recover.
04/8/2020
07:37
dealit: Let us hope this announcement as a positive effect on the s/p:- Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces that it has been granted UK and US patents for the LiquiBand® Exceed range, providing protection until 2034. The design of the applicator, tip and the raw materials used to manufacture the device has allowed it to be distinguished as a novel, patentable technology. These patents provide long-term protection on a core growth driver for the global LiquiBand® portfolio, covering 30-35% of the current product range. In addition, the UK patent will provide an additional tax benefit to the Group via the UK patent box scheme that is expected to reduce the effective tax rate for the Group by between 1% and 2% throughout the patent life. Chris Meredith, Chief Executive Officer of AMS, commented: "With end sales demand for LiquiBand® in the US showing early signs of recovery demonstrated by market share gains in the first quarter of 2020, these newly granted patents will further strengthen and protect growth in our core markets. They also highlight AMS's continued ability to design, develop and sell innovative, patentable technology."
ADVFN Advertorial
Your Recent History
LSE
AMS
Advanced M..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210423 09:51:08